How The Agios Pharmaceuticals (AGIO) Story Is Shifting After Aqvesme Approval And New Targets [Yahoo! Finance]
Agios Pharmaceuticals, Inc. (AGIO)
Last agios pharmaceuticals, inc. earnings: 4/30 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.agios.com/investor-overview
Company Research
Source: Yahoo! Finance
The updated fair value estimate for Agios Pharmaceuticals has shifted to US$38.88 from US$36.75, while several bullish analysts are now guiding price targets into the mid US$20s to mid US$30s. Those targets are being framed around the recent approval of Aqvesme, sector conditions in biotech, and differing views on how much risk to assign at current levels, with JPMorgan holding a Neutral stance alongside a US$25 target. As you read on, you will see how these moving targets fit into the broader story and how to track the evolving analyst narrative around Agios. Stay updated as the Fair Value for Agios Pharmaceuticals shifts by adding it to your watchlist or portfolio . Alternatively, explore our Community to discover new perspectives on Agios Pharmaceuticals. What Wall Street Has Been Saying ?? Bullish Takeaways BofA increased its price target on Agios Pharmaceuticals to US$35 from US$34 and keeps a Buy rating, which signals confidence in the company at current valuation level
Show less
Read more
Impact Snapshot
Event Time:
AGIO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AGIO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AGIO alerts
High impacting Agios Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
AGIO
News
- Levi & Korsinsky Reminds Agios Pharmaceuticals, Inc. Investors of the Ongoing Investigation into Potential Violations of Securities Laws - AGIOPR Newswire
- Agios Pharmaceuticals, Inc. Investigated by Shareholder Rights Advocates - Investors Should Contact The Gross Law Firm Regarding Potential Securities Law Violations - AGIOPR Newswire
- Agios Pharmaceuticals Teases 2026 Catalysts as PYRUKYND Thalassemia Launch Gains Early Traction [Yahoo! Finance]Yahoo! Finance
- Agios' PYRUKYND® (mitapivat) Approved for Adults with Thalassemia in the United Arab Emirates [Yahoo! Finance]Yahoo! Finance
- Agios’ PYRUKYND® (mitapivat) Approved for Adults with Thalassemia in the United Arab EmiratesGlobeNewswire
AGIO
Earnings
- 2/12/26 - Miss
AGIO
Sec Filings
- 3/3/26 - Form 4
- 3/3/26 - Form 4
- 3/3/26 - Form 4
- AGIO's page on the SEC website